Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $35.
Read original at benzingaStocks · News reference
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 6:34 PM
- Checked
- Aug 6, 2026, 6:34 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Biodesix Affirms FY2026 Sales Guidance of $108.000M-$114.000M vs $110.996M Est
Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.
Read original at benzingaBiodesix Q2 EPS $(0.71) Beats $(0.91) Estimate, Sales $26.861M Beat $26.026M Estimate
Read original at benzinga